TIDMAGL
RNS Number : 6622G
Angle PLC
28 July 2021
For immediate release 28 July 2021
ANGLE plc ("the Company")
CONTRACT SECURED WITH NEW PHARMA SERVICES CUSTOMER FOR BESPOKE
ASSAY DEVELOPMENT
ANGLE to develop two custom CTC assays to look at biomarkers of
DNA damage repair
Validated assays expected to be used for longitudinal analysis
in clinical trial
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy
company, is delighted to announce that it has agreed a pharma
services contract with another new customer for its recently
established pharma services business. ANGLE has been selected to
develop immunofluorescence (IF) assays using its Parsortix(R)
system to detect two specific protein markers expressed by
circulating tumour cells (CTCs) and implicated in DNA damage repair
(DDR), an increasing area of focus for oncology drug development.
The new customer is a well-funded clinical stage development
company with established commercialisation agreements with multiple
global pharma companies.
As part of the contract, ANGLE will develop the two assays to
detect the target proteins in four hard-to-treat cancers: triple
negative breast cancer, prostate cancer (including metastatic
and/or castration resistant), ovarian cancer (including high grade)
and pancreatic cancer. The assays will be developed in ANGLE's UK
R&D facility before being validated in ANGLE's clinical
laboratories.
The first phase of work agreed covers the initial assay
development and validation contract generating revenues of c. US$
400,000 over a 12 month period. Assuming a successful outcome, the
customer expects the assays to be utilised in a clinical trial with
study sites in the United States and Europe, planned to commence in
H2 2022. The clinical trial phase will incorporate longitudinal
analysis of patient samples (for example before, during and after
treatment with the investigational drug) and is expected to
generate further significant revenues for ANGLE. The same customer
also has other separate assay development projects, which it is
discussing with ANGLE.
The incorporation of bespoke assay development as a first phase
in pharma services is a major development for ANGLE, which is
expected to significantly increase the attraction of the Parsortix
CTC analysis offering, as pharma clients can look at proteins on
CTCs which directly align with the mechanism of operation of their
drug under investigation.
Once developed, the new assays will remain in the ownership of
ANGLE and be added to ANGLE's menu of pre-developed tests that can
be offered to other pharma customers. As in this case, pharma
companies are commonly interested in investigating protein markers
on actual cancer cells. These cannot be investigated using the
alternative liquid biopsy approach ctDNA (fragments of dead cancer
cells) since protein cannot be measured on ctDNA. Tissue biopsies
provide cancer cells but cannot be used for longitudinal monitoring
since only a single time point is usually possible with tissue
biopsy. Consequently, pharma companies are unable to access this
analysis without analysing CTCs.
ANGLE Founder and Chief Executive, Andrew Newland,
commented:
"We are delighted to have secured our first assay development
contract so soon after launching this service. Research by leading
cancer centres has demonstrated the utility of the Parsortix
platform in detecting novel drug targets expressed by CTCs and this
contract to develop assays against new targets of interest provides
further endorsement of our technology. DNA damage repair (DDR) is a
growing area of interest in new drug development and assay
development. The new assays will provide an important addition to
our pharma services menu alongside our existing capabilities in
PD-L1 for immunotherapy."
For further information ANGLE:
ANGLE plc +44 (0) 1483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
Andrew Holder, Head of Investor Relations
finnCap Ltd (NOMAD and Joint Broker)
Corporate Finance - Carl Holmes, Simon
Hicks, Teddy Whiley
ECM - Alice Lane, Sunila de Silva +44 (0)20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes, Nigel Birks +44 (0) 203 705 9330
FTI Consulting
Simon Conway, Ciara Martin +44 (0) 203 727 1000
Matthew Ventimiglia (US) +1 (212) 850 5624
This announcement contains inside information for the purposes
of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it
forms part of UK domestic law by virtue of the European Union
(Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with
the Company's obligations under Article 17 of MAR.
For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a world leading liquid biopsy company with
sample-to-answer solutions. ANGLE's proven patent protected
platforms include a circulating tumor cell (CTC) harvesting
technology and a downstream analysis system for cost effective,
highly multiplexed analysis of nucleic acids and proteins.
ANGLE's cell separation technology is called the Parsortix(R)
system, and it enables a liquid biopsy (a simple blood test) to be
used to provide the cells of interest to the user in a format
suitable for multiple types of downstream analyses. The system is
based on a microfluidic device that captures cells based on a
combination of their size and compressibility. The system is
epitope independent and can capture all types of CTCs as well as
CTC clusters in a viable form (alive). CTCs enable the complete
picture of a cancer to be seen as being an intact cell they allow
DNA, RNA and protein analysis and may provide comparable analysis
to a tissue biopsy. Because CTC analysis is a non-invasive process,
unlike tissue biopsy, it can be repeated as often as needed. This
is important because cancer develops and changes over time and
there is a clear medical need for up-to-date information on the
status of a patient's tumor. In addition, the live CTCs harvested
by the Parsortix system can be cultured, which offers the potential
for testing tumor response to drugs outside the patient.
The Parsortix technology is the subject of 26 granted patents in
Europe, the United States, China, Australia, Canada, India, Japan
and Mexico with three extensive families of patents are being
progressed worldwide.
The Parsortix system has a CE Mark in Europe for the indicated
use and, in the United States, a De Novo Submission has been made
to FDA for the Parsortix(R) PC1 system seeking FDA clearance with
Class II Classification for use with metastatic breast cancer
patients. FDA clearance is seen as the global standard. ANGLE is
seeking to be the first ever FDA cleared system for harvesting CTCs
for subsequent analysis.
ANGLE has also completed two separate 200 subject clinical
studies under a program designed to develop an ovarian cancer
pelvic mass triage test, with the results showing best in class
accuracy (AUC-ROC) of 95.1%. The pelvic mass triage assay has
undergone further refinement and optimisation and is currently in
the process of a 200 patient clinical verification study.
ANGLE's technology for the multiplex evaluation of proteins and
nucleic acids of all types is called the HyCEADTM Ziplex(R)
platform and is based on a patented flow through array technology.
It provides for low cost, highly multiplexed, rapid and sensitive
capture of targets from a wide variety of sample types. A
proprietary chemistry approach (the HyCEAD method) allows for the
capture and amplification of over 100 biomarkers simultaneously in
a single reaction. The HyCEAD Ziplex system is extremely sensitive
and is ideal for measuring gene expression and other markers
directly from Parsortix harvests and was used in the ovarian cancer
pelvic mass triage test to achieve best in class accuracy (AUC-ROC)
of 95.1%.
ANGLE's proprietary technologies can be combined to provide
automated, sample-to-answer results in both centralised laboratory
and point-of-use cartridge formats.
ANGLE has established formal collaborations with world-class
cancer centres and major corporates such as Abbott, Philips and
QIAGEN, and works closely with leading CTC translational research
customers. These Key Opinion Leaders (KOLs) are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. The body of evidence as to the benefits of the Parsortix
system is growing rapidly from our own clinical studies in
metastatic breast cancer and ovarian cancer and also from KOLs with
46 peer-reviewed publications and numerous publicly available
posters, available on our website.
ANGLE has established clinical services laboratories in the UK
and USA to accelerate commercialisation of the Parsortix system and
act as demonstrators to support product development. The
laboratories offer services to pharmaceutical and biotech customers
for use of the Parsortix system in cancer drug trials and, once the
laboratories are accredited, and tests validated, will provide
Laboratory Developed Tests (LDTs) for patient management.
, the news service of the London Stock Exchange. RNS is approved by
the Financial Conduct Authority to act as a Primary Information
Provider in the United Kingdom. Terms and conditions relating to
the use and distribution of this information may apply. For further
information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
CNTQDLFLFDLBBBF
(END) Dow Jones Newswires
July 28, 2021 02:00 ET (06:00 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2023 to Apr 2024